Aspira Women’s Health Announces $1.935 Million Private Placement Equity Financing
Summary
AUSTIN, Texas, July 01, 2024 (GLOBE NEWSWIRE) -- Aspira Womens Health Inc. (Aspira or the Company) (Nasdaq: AWH), a bio-analytical based womens health company focused on the development of gynecologic disease diagnostic tools, today announced it has entered into a securities purchase agreement dated June 30, 2024 with certain existing accredited shareholders and Company insiders to issue and sell an aggregate of 1,264,739 shares of its common stock (Common Stock) and warrants to purchase an equal number of shares of Common Stock (Warrants) at a combined offering price of $1.53 per share and warrant through a private placement financing (the Offering). Net proceeds from the Offering will support Aspiras ongoing commercial activities as well as general corporate purposes and working capital.The strong participation in this financing by our existing shareholders demonstrates firm support for Aspira at an important point in our growth, said Nicole Sandford, Aspiras CEO. We are laser-focused on commercial growth following the expansion of our OvaSuite test portfolio and the publication of compelling clinical data earlier this quarter. We believe we are well on our way to changing the standard of care for the 1.2 to 1.5 million U.S. women diagnosed with an adnexal mass each year.The securities being issued and sold in this private placement have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws, and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. Aspira has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued in the private placement.This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.